Reading Time: 5 minutesThe top-line results of the Modifying Immune Response and OutComes in ALS (MIROCALS) clinical trial were announced on 6 December 2022 at the 33rd International Symposium
Category: Clinical Trials
Reading Time: 2 minutesThis blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type correspond
Reading Time: 5 minutesThis blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type
Reading Time: 5 minutesThis blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type
Reading Time: 2 minutesThis blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type correspond
Reading Time: 6 minutesOn 29th September 2022 AMX0035, a treatment for Motor Neurone Disease (MND) was approved by the Food and Drug Administration (FDA) in the United States.
Reading Time: 5 minutesIn this guest blog written by Harry Bowles and Sarah Opie-Martin from King’s College London they discuss their MND research poster which was presented at
Reading Time: 6 minutesUpdate 21/09/2022: The results of the VALOR trial and its open label extension were published in the New England Journal of Medicine. These results give
Reading Time: 6 minutesThis year is set to be an exciting time for MND research, and we are especially hopeful that MND clinical trials will take centre stage
Reading Time: 7 minutesLast month saw the two-year anniversary since the first COVID lockdown in England (the UK) which changed our lives forever – not least because of